-
Media Release
New Novartis data show more Cosentyx™-treated psoriasis patients achieved clear or almost clear skin (PASI 90) compared to Stelara®
-
Media Release
Novartis' heart failure medicine LCZ696 granted FDA priority review
-
Media Release
Novartis investigational dual bronchodilator significantly improved lung function compared to single bronchodilators in patients with moderate-to-severe COPD in phase III studies
-
Media Release
Novartis announces FDA approval for Jadenu™ to simplify treatment administration for patients with chronic iron overload
-
Media Release
Novartis presents new data at WCD that shows significant efficacy of Cosentyx® in patients with psoriasis of the palms, soles of feet and nails
-
Media Release
Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma
-
Media Release
Combination of Novartis drugs Tafinlar® and Mekinist® shows significant survival benefit in patients with metastatic melanoma
-
Media Release
Novartis launches 'Novartis Access', a portfolio of affordable medicines to treat chronic diseases in lower-income countries
-
Media Release
FDA approves Novartis drug Odomzo® (sonidegib) for locally advanced basal cell carcinoma (laBCC), a form of skin cancer
-
Media Release
Novartis' new heart failure medicine LCZ696 approved by FDA to reduce risk of cardiovascular death and heart failure hospitalization; now called Entresto™ (sacubitril/valsartan)
-
Media Release
Novartis Clarification on Specialty Pharmacy Settlement in Principle Announcement
-
Media Release
Novartis announces NEJM publication of secukinumab Phase III data confirming significant efficacy in patients with psoriatic arthritis